Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide
Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide
复制标题
DOI：
10.1016/j.diabres.2005.04.002
复制
发表时间：
2005-12-01
影响因子：
5.1
通讯作者：
Oka, Y
中科院分区：
文献类型：
--
作者：
Satoh, J;Takahashi, K;Oka, Y
我们回顾评估了接受格列齐特(GCZ)和格列本脲(GBC)治疗的2型糖尿病患者在开始胰岛素治疗之前可能存在的差异，因为GCZ可能比GBC对β细胞具有保护作用。受试者为日本患者。GCZ组为单用GCZ或与其他口服降糖药(OHAs)合用或联合治疗；GBC组为单用GBC或联合GCZ以外的其他OHAs。使用Kaplan-Meier方法计算胰岛素治疗开始前的时间。比例风险模型用于调整GCZ组和GBC组之间的不同变量。与GBC组相比，GCZ组从糖尿病发病、糖尿病治疗、GCZ或GBC治疗开始到胰岛素治疗开始的时间显著延长(P<；各组均为0.001)。影响这一时期的独立变量是GCZ或GBC治疗期间的平均HbA1c水平(危险比=2.5‰)，其他OHAs合并(联合危险比=1.9)，以及GCZ组和GBC组之间的差异(GCZ危险比=0.5)。这些结果表明，GCZ可能比GBC对继发性β细胞衰竭有更好的保护作用。(C)2005爱思唯尔爱尔兰有限公司。保留所有权利。
We retrospectively evaluated a possible difference in periods until start of insulin treatment between type 2 diabetic patients treated with gliclazide (GCZ) and glibenclamide (GBC), because GCZ might be protective for beta cells than GBC. Subjects were Japanese patients. GCZ group consisted of patients treated with GCZ alone or with GCZ and GBC in the separate treatment periods in combination with or without other oral hypoglycemic agents (OHAs), while GBC group consisted of patients with GBC alone or in combination with other OHAs except GCZ. The periods until the treatment of insulin commenced were calculated using the Kaplan-Meier method. Proportional hazards models were used to adjust the differing variables between GCZ and GBC groups. The periods until the start of insulin treatment from diabetes onset, diabetes treatment, or GCZ or GBC treatment were significantly longer in the GCZ group than those in GBC group (P < 0.001 in each group). Independent variables affecting the period were average HbA1c levels during GCZ or GBC treatment (hazard ratio = 2.5 per %), other OHAs combined (hazard ratio = 1.9 on combination), and difference between GCZ and GBC groups (hazard ratio = 0.5 on GCZ). These results imply that GCZ may be more protective against secondary beta cell failure than GBC. (c) 2005 Elsevier Ireland Ltd. All rights reserved.